PaxVax Presents Phase 1 Clinical Trial Data for Single-Dose Cholera Vaccine

Vaccine Candidate Found to be Well Tolerated and Immunogenic

Menlo Park, Calif., and Atlanta – November 14, 2012 – PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner today announced results from a Phase 1 clinical trial of PaxVax’s single-dose oral cholera vaccine candidate at the 2012 American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting in Atlanta. The results were presented by the company’s collaborator, Dr. Wilbur Chen of the University of Maryland, Baltimore. The vaccine candidate, PXVX0200 (also known as CVD 103-HgR), was found to be well tolerated and immunogenic.

Pages

Cholera

18.97
-72.29

Anthrax

40.71
-74.01

Typhoid

21.00
78.00

Hepatitis A

39.92
32.83

H5N1, Dengue

& HIV

-0.78
113.92

for protection wherever you are and wherever you go

PaxVax is a fully integrated specialty vaccine company committed to developing and commercializing innovative vaccines against infectious diseases.

PaxVax: Better Vaccines

37.44
-122.14
Subscribe to PaxVax - Socially Responsible Vaccines RSS